Platform Technology
BEPO® Technology
AIC's therapies utilize BEPO®, Medincell's cutting-edge Long-Acting Injectable polymer platform — a clinically validated, commercially proven
drug delivery system.
Euronext: MEDCL
The Platform
What is BEPO®?
BEPO® is a biodegradable, injectable sustained-release technology developed by Medincell (Montpellier, France; EPA: MEDCL). It is based on a viscous non-aqueous copolymer mixture of polylactic acid (PLA) and polyethylene glycol (PEG) that, upon contact with aqueous fluids, self-assembles into a semi-solid depot at the site of injection.
The depot slowly biodegrades over days to weeks, releasing the encapsulated drug in a controlled, sustained manner — eliminating the need for repeated dosing and maintaining therapeutic concentrations at the target site.
The technology is ready-to-use, requires no reconstitution or mixing, and does not require specialized training to administer — making it highly practical for surgical and clinical settings.
Biodegradable
PLA-PEG polymer safely degrades in biological tissue — no removal required.
Injectable Depot
Viscous liquid injected at the target site; solidifies on contact with aqueous fluid.
Sustained Release
Controlled drug release over days to weeks from a single administration.
Ready-to-Use
No mixing, reconstitution, or specialized equipment required.
Versatile
Compatible with a broad range of small molecule drugs and biologics.
Proven in the Clinic
Commercial Validation
FDA Approved — April 2023
UZEDY® (risperidone)
The first BEPO®-based commercial product. Marketed by Teva Pharmaceuticals in the United States for schizophrenia, with once- or twice-monthly subcutaneous dosing.
FDA Approved — October 2026
WELTRUZA™ (olanzapine)
The second BEPO®-based commercial product. The first and only once-monthly LAI formulation of olanzapine — no loading doses, no oral supplementation, no post-injection monitoring required.
Two FDA approvals confirm BEPO® has achieved:
Large-scale GMP manufacturing
Repeat FDA approval across two distinct molecules
Established safety profile in clinical trials and post-market use
Commercial launch in the United States
Long-term partnership with a global Top-10 pharma
Industry Validation
Strategic Pharmaceutical Partnerships
Medincell has established collaborations with leading global pharmaceutical companies to apply BEPO® technology across multiple therapeutic areas.
Teva Pharmaceuticals
Teva licensed Medincell's BEPO® long-acting injectable technology platform (commercialized as SteadyTeq™) for CNS programs including UZEDY® and WELTRUZA™. Medincell is eligible for development and commercial milestone payments plus mid- to high-single-digit royalties on worldwide sales. UZEDY® was approved in 2023 and WELTRUZA™ received FDA approval in October 2026 — marking the second commercial product from this collaboration.
AbbVie
In April 2024, AbbVie entered into a strategic co-development and licensing agreement with Medincell covering up to six long-acting injectable programs across multiple therapeutic areas. Medincell received a $35 million upfront payment and is eligible for up to $1.9 billion in development and commercial milestones ($315 million per program), plus mid-single to low-double-digit royalties on worldwide net sales.
Additional licensees include the Bill & Melinda Gates Foundation (global health applications) and Corbion (biomaterials), further demonstrating the breadth of BEPO®'s applicability and Medincell's position as a leading sustained-release drug delivery company.
Learn More About F14
See how BEPO® technology is applied in AIC's lead program for post-TKR pain and inflammation.